JAZZ vs PLUS · P/E 1988, rev $4.07B vs P/E 17, rev $2.07B
Jazz Pharmaceuticals PLC (JAZZ) versus ePlus inc (PLUS) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Not investment advice. Open the JAZZ and PLUS stock pages for the full models.
Not investment advice.